Why 2020 Could Be Another Historic Year for Apple
Apple shares are holding near all-time highs, but this is not stopping analysts for calling for the stock to run even higher. Wedbush just came out with a report calling for Apple to add…
All Work
Chris Lange
What to Expect When Walgreens Reports Wednesday
Walgreens is scheduled to release its fiscal first-quarter financial results before the markets open on Wednesday.
Wedbush’s Top Tech Predictions for 2020
Wedbush believes that there is clear momentum for the tech stocks as a number of transformational trends will be front and center for Wall Street.
Is SmileDirectClub’s Walmart Partnership the Beginning of Something Big?
SmileDirectClub shares jumped on Monday after the firm announced a partnership with Walmart that makes it the first provider of clear aligner therapy to offer oral care products in mass retail.
Walgreens, Lennar, Bed Bath & Beyond, KB Home and More Earnings Coming This Week
24/7 Wall St. has put together a preview of the most prominent earnings reports expected in the first full trading week to start the New Year.
Minimizing IPO Investing Risks in 2020: The ETFs to Own
In an effort to mitigate this risk and concern about picking the winners or the losers with each company that comes public, exchange-traded funds are available that offer a sampling and exposure to the…
The Top Biotech ETFs to Watch in 2020
On a company by company basis, investing in biotechs is somewhat tricky. However, there is an investment strategy that makes it much easier.
Why Canaccord Genuity Is Now Tesla’s Biggest Bull
Tesla shares have absolutely exploded in the past six months, and the cult of Elon Musk is growing, due to many exciting developments from Tesla recently, including the Cybertruck.
Making Social Media Investing Easier: ETFs to Buy in 2020
Picking a single social media stock like Facebook or Twitter can be profitable, but with that comes a lack of diversity the average investor might need.
Will 2020 Be Another Breakout Year for Semiconductors? These Are The ETFs to Own
Investors can use a number of exchange-traded funds to invest in the volatile semiconductor industry.
The Top Biopharma Events to Watch in 2020
Here, 24/7 Wall St. presents a calendar of a few of the biggest clinical trial and FDA updates to watch for in early 2020.
Why This Hairy Cell Leukemia Treatment Could Be Big in Europe
Innate Pharma shares jumped on Thursday after the firm announced that the European Medicines Agency has accepted the Marketing Authorization Application for Lumoxiti for adult patients with relapsed or refractory hairy cell leukemia.
Why One Analyst Thinks 2020 Could Be Huge for Amazon
Independent research firm Argus notes that the number of Amazon items delivered with Prime one-day and Prime same-day delivery nearly quadrupled from the prior year.
Why This Refractory Angina Treatment Could Be a Big Hit
Neovasc shares nearly doubled on Tuesday after the firm announced the submission of an application to the FDA for its Neovasc Reducer medical device for the treatment of refractory angina.
Is It Over for This Huntington’s Disease Clinical Trial?
Wave Life Sciences shares dropped sharply to start out the week after the company announced topline data from its ongoing midstage trial in Huntington’s disease.
Why One Analyst Sees Sarepta’s Roche Deal Taking Off
Sarepta shares jumped last week on news that the company reached a licensing deal with Roche. While investors saw about a five-point bump from this news, one analyst sees much more upside for this…
Wedbush’s Top 10 Tech Predictions for 2020
Wedbush believes that there is clear momentum for the tech stocks in 2020 as a number of transformational trends such as 5G, cloud, autonomous and the streaming content wars will be front and center.
Why This aPAP Treatment Is a Big Hit
Savara shares more than doubled on Monday after the firm announced that the FDA has granted Breakthrough Therapy designation for its autoimmune pulmonary alveolar proteinosis treatment Molgradex.
AstraZeneca’s FDA Nod Could Be Big
AstraZeneca has announced that the FDA has approved its companion diagnostic test that identifies patients with metastatic pancreatic cancer.
Disney Makes Case for Being Legitimate Death Star in US Box Office
Disney topped the weekend box office for the second straight time, notching a cool $72 million in North American ticket sales.